AstraZeneca’s Tezepelumab Fails to Meet its Primary Endpoint in P-III SOURCE Study for Asthma

December 22, 2020 Auto Bot Asthma, AstraZeneca, Clinical Trials, P-III, patients, reports, results, Severe, Tezepelumab, Trial 0

Shots:

  • The P-III SOURCE study involves assessing Tezepelumab (210mg, q4w) vs PBO in 150 adult patients as add-on therapy with patients maintained on their currently prescribed ICS + LABA, with/ out other asthma controller therapy for 48wks.
  • The trial did not meet its 1EPs i.e., reduction in the daily OCS dose, without loss of asthma control, the safety profile was consistent with previous trials. The therapy’s other efficacy parameters were similar to those observed in previous trials, including the P-III NAVIGATOR trial
  • Tezepelumab is a human mAb targeting TSLP, being developed in collaboration with AstraZeneca and Amgen

Click here ­to­ read full press release/ article | Ref: AstraZeneca  | Image: Physicians Practice

The post AstraZeneca’s Tezepelumab Fails to Meet its Primary Endpoint in P-III SOURCE Study for Asthma first appeared on PharmaShots.